Skip to search formSkip to main contentSkip to account menu

ispinesib

A synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (2)

BenzamidesQuinazolines
CK0238273Ispinesib MesylateKIF11 protein, humanNCIt Antineoplastic Agent Terminology

Narrower (1)

SB 715992

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression.
2011
2011
Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia
2009
2009
Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
Current antimitotic cancer chemotherapy based on vinca alkaloids and taxanes target tubulin, a protein required not only for… 
2009
2009
A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression
PurposeIspinesib, a kinesin spindle protein inhibitor, blocks assembly of a functional mitotic spindle, leading to G2/M arrest… 
2007
2007
A Bayesian Population PK–PD Model of Ispinesib‐induced Myelosuppression
The goal of the present analysis is to fit a Bayesian population pharmacokinetic pharmacodynomic (PK–PD) model to characterize… 
2007
2007
University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC)
15573 Background: Ispinesib is a novel kinesin spindle protein inhibitor that has significant antitumor activity in multiple… 
2007
2007
A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer
5562 Background: Kinesin spindle protein (KSP) is required for mitotic spindle bipolarity and cell cycle progression. Ispinesib… 
2006
2006
A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors.
2026 Background: Ispinesib, a novel cytotoxic agent inhibiting the kinesin spindle protein (KSP) has demonstrated significant… 
2006
2006
Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.
2027 Background: Kinesin spindle protein (KSP) is required for establishment of mitotic spindle bipolarity and cell cycle… 
2006
2006
A randomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P).
3595 Background: Ispinesib(SB-715992) is a polycyclic, nitrogen-containing heterocycle that inhibits the mitotic kinesin spindle… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)